Enhance tumor radiosensitivity by intracellular delivery of eukaryotic translation initiation factor 4E binding proteins

Medical Hypotheses

Volumn 76, Issue 2, 2011, Pages 246-248

  Tian, Shuang ^a,b   Li, Xiu Li ^b   Shi, Mei ^a   Yao, Yuan Qing ^b   Li, Li Wen ^c   Xin, Xiao Yan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c NORTHWEST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EUKARYOTIC TRANSLATION INITIATION FACTOR 4E BINDING PROTEIN; HYBRID PROTEIN; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN KINASE B; PROTEIN VP22; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE PERMEABILITY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; TUMOR GROWTH;

ANOXIA; ANTINEOPLASTIC AGENTS; EUKARYOTIC INITIATION FACTOR-4E; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INHIBITOR OF APOPTOSIS PROTEINS; MODELS, BIOLOGICAL; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; RADIATION TOLERANCE; RECOMBINANT FUSION PROTEINS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EUKARYOTA; HUMAN HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA; PROKARYOTA;

EID: 78651108147     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.10.010     Document Type: Article

References (36)

1. Mavrakis K.J., Wendel H.G. Translational control and cancer therapy. Cell Cycle 2008, 7(18):2791-2794.
2. Silva R.L., Wendel H.G. MNK, EIF4E and targeting translation for therapy. Cell Cycle 2008, 7(5):553-555.
3. Konicek B.W., Dumstorf C.A., Graff J.R. Targeting the eIF4F translation initiation complex for cancer therapy. Cell Cycle 2008, 7(16):2466-2471.
4. Dong K., Wang R., Wang X., Lin F., Shen J.J., Gao P., et al. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells. Breast Cancer Res Treat 2009, 113(3):443-456.
5. Soni A., Akcakanat A., Singh G., Luyimbazi D., Zheng Y., Kim D., et al. EIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 2008, 7(7):1782-1788.
6. Graff J.R., Konicek B.W., Vincent T.M., Lynch R.L., Monteith D., Weir S.N., et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 2007, 117(9):2638-2648.
7. Foged C., Nielsen H.M. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv 2008, 5(1):105-117.
8. Foerg C., Merkle H.P. On the biomedical promise of cell penetrating peptides: limits versus prospects. J Pharm Sci 2008, 97(1):144-162.
9. Edenhofer F. Protein transduction revisited: novel insights into the mechanism underlying intracellular delivery of proteins. Curr Pharm Des 2008, 14(34):3628-3636.
10. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 2006, 4(9):601-605.
11. Moeller B.J., Dewhirst M.W. HIF-1 and tumour radiosensitivity. Br J Cancer 2006, 95(1):1-5.
12. Moeller B.J., Dreher M.R., Rabbani Z.N., Schroeder T., Cao Y., Li C.Y., et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 2005, 8(2):99-110.
13. Semenza G.L. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004, 5(5):405-406.
14. Pore N., Jiang Z., Shu H.K., Bernhard E., Kao G.D., Maity A. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 2006, 4(7):471-479.
15. Harada H., Itasaka S., Kizaka-Kondoh S., Shibuya K., Morinibu A., Shinomiya K., et al. The Akt/mTOR pathway assures the synthesis of HIF-1alpha protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. J Biol Chem 2009, 284(8):5332-5342.
16. Shi M., Guo X.T., Shu M.G., Chen F.L., Li L.W. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers. Med Hypotheses 2007, 69(1):33-35.
17. Rodel F., Hoffmann J., Distel L., Herrmann M., Noisternig T., Papadopoulos T., et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005, 65(11):4881-4887.
18. Capalbo G., Rodel C., Stauber R.H., Knauer S.K., Bache M., Kappler M., et al. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlenther Onkol 2007, 183(11):593-599.
19. Rodel F., Hoffmann J., Grabenbauer G.G., Papadopoulos T., Weiss C., Gunther K., et al. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002, 178(8):426-435.
20. Knutsen A., Adell G., Sun X.F. Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2004, 60(1):149-155.
21. Rodel F., Frey B., Leitmann W., Capalbo G., Weiss C., Rodel C. Survivin antisense oligonucleotides effectively radiosensitize colorectal cancer cells in both tissue culture and murine xenograft models. Int J Radiat Oncol Biol Phys 2008, 71(1):247-255.
22. Shi M, Guo XT, Shu MG, Li LW. Enhancing tumor radiosensitivity by intracellular delivery of survivin antagonists. Med Hypotheses; 2006.
23. Guan H.T., Xue X.H., Dai Z.J., Wang X.J., Li A., Qin Z.Y. Down-regulation of survivin expression by small interfering RNA induces pancreatic cancer cell apoptosis and enhances its radiosensitivity. World J Gastroenterol 2006, 12(18):2901-2907.
24. Asanuma K., Kobayashi D., Furuya D., Tsuji N., Yagihashi A., Watanabe N. A role for survivin in radioresistance of pancreatic cancer cells. Jpn J Cancer Res 2002, 93(9):1057-1062.
25. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008, 11(1-2):32-50.
26. Brachmann S., Fritsch C., Maira S.M., Garcia-Echeverria C. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 2009, 21(2):194-198.
27. Goodfellow I.G., Roberts L.O. Eukaryotic initiation factor 4E. Int J Biochem Cell Biol 2008, 40(12):2675-2680.
28. Paglin S., Lee N.Y., Nakar C., Fitzgerald M., Plotkin J., Deuel B., et al. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res 2005, 65(23):11061-11070.
29. Shinohara E.T., Cao C., Niermann K., Mu Y., Zeng F., Hallahan D.E., et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005, 24(35):5414-5422.
30. Albert J.M., Kim K.W., Cao C., Lu B. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 2006, 5(5):1183-1189.
31. Cao C., Subhawong T., Albert J.M., Kim K.W., Geng L., Sekhar K.R., et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006, 66(20):10040-10047.
32. Jiang B.H., Liu L.Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 2008, 11(3):63-76.
33. Manegold P.C., Paringer C., Kulka U., Krimmel K., Eichhorn M.E., Wilkowski R., et al. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res 2008, 14(3):892-900.
34. Murphy J.D., Spalding A.C., Somnay Y.R., Markwart S., Ray M.E., Hamstra D.A. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res 2009, 15(2):589-596.
35. Wang X., Yue P., Kim Y.A., Fu H., Khuri F.R., Sun S.Y. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008, 68(18):7409-7418.
36. Garber K. Targeting mTOR: something old, something new. J Natl Cancer Inst 2009, 101(5):288-290.